
Chinese General Practice ›› 2023, Vol. 26 ›› Issue (16): 1979-1983.DOI: 10.12114/j.issn.1007-9572.2022.0547
Special Issue: 内分泌代谢性疾病最新文章合辑; 男性健康最新文章合辑; 老年问题最新文章合辑; 老年人群健康最新文章合辑
• Original Research·Focus on Population Health • Previous Articles Next Articles
Received:2022-05-09
Revised:2023-03-05
Published:2023-06-05
Online:2023-03-16
Contact:
LI Chunlin
通讯作者:
李春霖
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0547
| 组别 | 例数 | 年龄( | BMI( | 糖尿病病程( | FPG( | 2 hPG( | HbA1c( | MAGE( | 血糖变异系数( |
|---|---|---|---|---|---|---|---|---|---|
| TIR<85% | 59 | 79.8±8.3 | 24.4±2.5 | 19.8±10.3 | 6.3±2.0 | 10.9±3.0 | 7.7±1.4 | 5.2±1.5 | 27.8±9.1 |
| TIR≥85% | 141 | 75.3±9.1 | 25.4±2.5 | 13.2±8.1 | 5.8±1.4 | 8.9±2.6 | 6.8±1.2 | 3.1±1.2 | 17.5±5.8 |
| t(χ2)值 | -3.295 | 2.707 | -4.888 | -2.045 | -4.649 | -4.606 | -10.279 | -9.545 | |
| P值 | 0.001 | 0.007 | <0.001 | 0.043 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 组别 | 收缩压( | 舒张压( | TC( | TG( | LDL-C( | HDL-C( | 服用二甲双胍〔n(%)〕 | 服用磺胺类药物〔n(%)〕 | 使用胰岛素〔n(%)〕 |
| TIR<85% | 129±11 | 71±8 | 4.25±0.92 | 1.39±0.79 | 2.48±0.79 | 1.16±0.33 | 30(50.8) | 11(18.6) | 44(74.6) |
| TIR≥85% | 126±11 | 71±8 | 4.17±0.83 | 1.49±0.89 | 2.42±0.69 | 1.12±0.32 | 68(48.2) | 43(30.5) | 48(34.0) |
| t(χ2)值 | -1.500 | 0.001 | -0.583 | 0.812 | -0.519 | -0.774 | 0.114a | 2.965a | 27.512a |
| P值 | 0.135 | 0.999 | 0.561 | 0.418 | 0.605 | 0.440 | 0.735 | 0.085 | <0.001 |
Table 1 Baseline clinical characteristics of participants with TIR<85% and those with TIR≥85%
| 组别 | 例数 | 年龄( | BMI( | 糖尿病病程( | FPG( | 2 hPG( | HbA1c( | MAGE( | 血糖变异系数( |
|---|---|---|---|---|---|---|---|---|---|
| TIR<85% | 59 | 79.8±8.3 | 24.4±2.5 | 19.8±10.3 | 6.3±2.0 | 10.9±3.0 | 7.7±1.4 | 5.2±1.5 | 27.8±9.1 |
| TIR≥85% | 141 | 75.3±9.1 | 25.4±2.5 | 13.2±8.1 | 5.8±1.4 | 8.9±2.6 | 6.8±1.2 | 3.1±1.2 | 17.5±5.8 |
| t(χ2)值 | -3.295 | 2.707 | -4.888 | -2.045 | -4.649 | -4.606 | -10.279 | -9.545 | |
| P值 | 0.001 | 0.007 | <0.001 | 0.043 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 组别 | 收缩压( | 舒张压( | TC( | TG( | LDL-C( | HDL-C( | 服用二甲双胍〔n(%)〕 | 服用磺胺类药物〔n(%)〕 | 使用胰岛素〔n(%)〕 |
| TIR<85% | 129±11 | 71±8 | 4.25±0.92 | 1.39±0.79 | 2.48±0.79 | 1.16±0.33 | 30(50.8) | 11(18.6) | 44(74.6) |
| TIR≥85% | 126±11 | 71±8 | 4.17±0.83 | 1.49±0.89 | 2.42±0.69 | 1.12±0.32 | 68(48.2) | 43(30.5) | 48(34.0) |
| t(χ2)值 | -1.500 | 0.001 | -0.583 | 0.812 | -0.519 | -0.774 | 0.114a | 2.965a | 27.512a |
| P值 | 0.135 | 0.999 | 0.561 | 0.418 | 0.605 | 0.440 | 0.735 | 0.085 | <0.001 |
| 组别 | 例数 | HbA1c检测次数(次) | HbA1c均值(%) | HbA1c变异系数(%) | HVS(分) |
|---|---|---|---|---|---|
| TIR<85% | 59 | 2.3±1.0 | 7.4±0.6 | 9.7±3.8 | 48.7±20.4 |
| TIR≥85% | 141 | 2.5±1.2 | 6.9±0.8 | 8.2±4.5 | 32.5±20.8 |
| t值 | 0.925 | -4.980 | -2.207 | -5.037 | |
| P值 | 0.356 | <0.001 | 0.028 | <0.001 |
Table 2 Comparison of HbA1c detection times and HbA1c variability indices between two groups during the follow-up
| 组别 | 例数 | HbA1c检测次数(次) | HbA1c均值(%) | HbA1c变异系数(%) | HVS(分) |
|---|---|---|---|---|---|
| TIR<85% | 59 | 2.3±1.0 | 7.4±0.6 | 9.7±3.8 | 48.7±20.4 |
| TIR≥85% | 141 | 2.5±1.2 | 6.9±0.8 | 8.2±4.5 | 32.5±20.8 |
| t值 | 0.925 | -4.980 | -2.207 | -5.037 | |
| P值 | 0.356 | <0.001 | 0.028 | <0.001 |
| 模型 | HbA1c均值 | HbA1c变异系数 | HVS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| b(95%CI) | P值 | R2 | b(95%CI) | P值 | R2 | b(95%CI) | P值 | R2 | |
| 单因素回归分析模型 | -0.02(-0.03,-0.01) | <0.001 | 0.156 | -0.06(-0.10,-0.03) | 0.001 | 0.057 | -0.55(-0.72,-0.37) | <0.001 | 0.160 |
| 多因素回归分析模型1 | -0.02(-0.02,-0.01) | <0.001 | 0.206 | -0.07(-0.10,-0.03) | 0.001 | 0.059 | -0.49(-0.68,-0.31) | <0.001 | 0.175 |
| 多因素回归分析模型2 | -0.01(-0.02,-0.01) | 0.001 | 0.326 | -0.07(-0.12,-0.03) | 0.003 | 0.100 | -0.47(-0.69,-0.25) | <0.001 | 0.229 |
| 多因素回归分析模型3 | -0.01(-0.02,0.00) | 0.002 | 0.329 | -0.07(-0.12,-0.03) | 0.003 | 0.100 | -0.44(-0.67,-0.21) | <0.001 | 0.234 |
Table 3 Multiple linear regression analysis of the influence of TIR on long-term HbA1c variability
| 模型 | HbA1c均值 | HbA1c变异系数 | HVS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| b(95%CI) | P值 | R2 | b(95%CI) | P值 | R2 | b(95%CI) | P值 | R2 | |
| 单因素回归分析模型 | -0.02(-0.03,-0.01) | <0.001 | 0.156 | -0.06(-0.10,-0.03) | 0.001 | 0.057 | -0.55(-0.72,-0.37) | <0.001 | 0.160 |
| 多因素回归分析模型1 | -0.02(-0.02,-0.01) | <0.001 | 0.206 | -0.07(-0.10,-0.03) | 0.001 | 0.059 | -0.49(-0.68,-0.31) | <0.001 | 0.175 |
| 多因素回归分析模型2 | -0.01(-0.02,-0.01) | 0.001 | 0.326 | -0.07(-0.12,-0.03) | 0.003 | 0.100 | -0.47(-0.69,-0.25) | <0.001 | 0.229 |
| 多因素回归分析模型3 | -0.01(-0.02,0.00) | 0.002 | 0.329 | -0.07(-0.12,-0.03) | 0.003 | 0.100 | -0.44(-0.67,-0.21) | <0.001 | 0.234 |
| 模型 | HbA1c均值 | HbA1c变异系数 | HVS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| b(95%CI) | P值 | R2 | b(95%CI) | P值 | R2 | b(95%CI) | P值 | R2 | |
| 单因素回归分析模型 | -0.02(-0.03,-0.01) | <0.001 | 0.186 | -0.09(-0.16,-0.03) | 0.003 | 0.081 | -0.72(-0.99,-0.45) | <0.001 | 0.213 |
| 多因素回归分析模型1 | -0.02(-0.03,-0.01) | <0.001 | 0.206 | -0.09(-0.16,-0.02) | 0.014 | 0.085 | -0.64(-0.95,-0.33) | <0.001 | 0.238 |
| 多因素回归分析模型2 | -0.01(-0.02,0.00) | 0.070 | 0.329 | -0.07(-0.16,0.01) | 0.098 | 0.140 | -0.45(-0.80,-0.09) | 0.014 | 0.330 |
| 多因素回归分析模型3 | -0.01(-0.02,0.00) | 0.142 | 0.342 | -0.07(-0.16,0.02) | 0.114 | 0.141 | -0.41(-0.77,-0.04) | 0.029 | 0.336 |
Table 4 Multiple linear regression analysis of the relationship of TIR and long-term HbA1c variability in the participants after removing the deceased and missing cases
| 模型 | HbA1c均值 | HbA1c变异系数 | HVS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| b(95%CI) | P值 | R2 | b(95%CI) | P值 | R2 | b(95%CI) | P值 | R2 | |
| 单因素回归分析模型 | -0.02(-0.03,-0.01) | <0.001 | 0.186 | -0.09(-0.16,-0.03) | 0.003 | 0.081 | -0.72(-0.99,-0.45) | <0.001 | 0.213 |
| 多因素回归分析模型1 | -0.02(-0.03,-0.01) | <0.001 | 0.206 | -0.09(-0.16,-0.02) | 0.014 | 0.085 | -0.64(-0.95,-0.33) | <0.001 | 0.238 |
| 多因素回归分析模型2 | -0.01(-0.02,0.00) | 0.070 | 0.329 | -0.07(-0.16,0.01) | 0.098 | 0.140 | -0.45(-0.80,-0.09) | 0.014 | 0.330 |
| 多因素回归分析模型3 | -0.01(-0.02,0.00) | 0.142 | 0.342 | -0.07(-0.16,0.02) | 0.114 | 0.141 | -0.41(-0.77,-0.04) | 0.029 | 0.336 |
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
戴冬君,陆静毅,张磊,等. 应用葡萄糖在目标范围内时间评价2型糖尿病血糖控制情况的适宜切点分析[J]. 中华医学杂志,2020,100(38):2990-2996. DOI:10.3760/cma.j.cn112137-20200619-01895.
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
American Diabetes Association. 6. Glycemic targets:standards of medical care in diabetes-2020[J]. Diabetes Care,2020,43(s1):66-76. DOI:10.2337/dc20-S006.
|
| [10] |
|
| [11] |
彭慧敏,邓洪容,周泳雯,等. 血糖变异性对1型糖尿病患者葡萄糖目标范围内时间与血糖管理指标关系的影响[J]. 中华医学杂志,2022,102(16):1190-1195. DOI:10.3760/cma.j.cn112137-20211009-02236.
|
| [12] |
田景琰,宁光. 管理糖化血红蛋白变异性 降低糖尿病患者全因死亡风险[J]. 中华内科杂志,2022,61(4):367-369. DOI:10.3760/cma.j.cn112138-20210622-00436.
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志,2021,37(4):311-398. DOI:10.3760/cma.j.cn311282-20210304-00142.
|
| [19] |
|
| [20] |
中华医学会内分泌学分会. 糖尿病患者血糖波动管理专家共识[J]. 中华内分泌代谢杂志,2017,33(8):633-636. DOI:10.3760/cma.j.issn.1000-6699.2017.08.002.
|
| [21] |
中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2021年版)[J]. 中华糖尿病杂志,2021,13(10):936-948. DOI:10.3760/cma.j.cn115791-20210810-00436.
|
| [1] | SHI Zhonghao, CHEN Yueying, DONG Xiaoyan, HOU Jiaqi, XUE Luan. Clinical Feature of Primary Sjögren's Syndrome Based on Quantitative Assessment of Blood Stasis Syndrome [J]. Chinese General Practice, 2026, 29(32): 4745-4751. |
| [2] | HU Jian, LIU Min, JIAO Zengtao, JING Wenzhan, LIANG Wannian. Research on the Risk Level Assessment of Respiratory Infectious Disease Transmission: a Case Study of COVID-19-infected Public Places [J]. Chinese General Practice, 2026, 29(32): 4738-4744. |
| [3] | LIN Zehua, ZHANG Lan, DAI Shanshan, WEI Yuanyuan, LI Xingli, MA Yingchun. Evaluation and Comparison of Multidimensional Functional Disability in Geriatric Comorbidities and Comorbid Acute Kidney Injury [J]. Chinese General Practice, 2026, 29(32): 4777-4782. |
| [4] | TANG Haoqing, LI Mingyue, LONG Ren, ZHU Yinbo, LIANG Weihuan, ZHU Ping, ZHAO Wei, ZHAO Yang, LIU Xiaoyun. Management Burden of Diabetic Mellitus Patients with Multimorbidity among Middle Aged and Older Adults: a Cross-sectional Survey in 6 Community Medical Institutes of China [J]. Chinese General Practice, 2026, 29(32): 4786-4797. |
| [5] | WANG Shiyi, FAN Xiaojing, SI Yafei, ZHOU Zhongliang. Advances in Key Measurement Techniques for the Intrinsic Capacity of Elderly in the Context of Healthy Aging [J]. Chinese General Practice, 2026, 29(31): 4662-4666. |
| [6] | WANG Zhongkai, WU Changyong, LI Menghan, LUO Yihua, ZHANG Bingqing, PENG Yunzhu. Association between Remnant Cholesterol Inflammatory Index and Risk of Cardiometabolic Multimorbidity in Middle-aged and Older Adults [J]. Chinese General Practice, 2026, 29(31): 4573-4581. |
| [7] | KUANG Li, DING Xinxin, MA Yuanzhu. Application of Motivational Interviewing in Healthcare Provider-Patient Communication for Chronic Disease Management in Primary Care: from Principles to Practice [J]. Chinese General Practice, 2026, 29(31): 4536-4542. |
| [8] | LI Bin, GE Mengfei, HAN Jing, XIAO Yu, ZHONG Yu. The Influencing Factors of Physical and Mental Health of the Elderly at Home in the Community and the Empowerment Strategies of Medical Social Workers [J]. Chinese General Practice, 2026, 29(31): 4627-4634. |
| [9] | HAN Leyang, ZHENG Huixian, TIAN Yiran, TANG Haoqing, LONG Ren, LI Daihan, LIU Xiaoyun. Measuring Integrated Services for Rural Chronic Disease Patients Based on Formative Measurement Theory [J]. Chinese General Practice, 2026, 29(31): 4543-4550. |
| [10] | TIAN Xiangyang, ZHOU Yingsheng, GAO Ying. Prospects of Behavioral and Lifestyle Interventions for Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(31): 4513-4520. |
| [11] | XIAO Zhili, LU Chenxia, ZHU Hui, ZHANG Jia, CHEN Zhuangzhuang, SUN Wei, LIU Xiangchuxuan, LUO Cheng, XIAO Mingzhong, LI Xiaodong. Application and Future Prospects of CGM Technology in Co-management of MAFLD and T2DM [J]. Chinese General Practice, 2026, 29(31): 4521-4527. |
| [12] | WEI Xuejuan, WANG Lihua, WANG Li, REN Jinglin, YAN Haiqing, YU Haiyang, LIU Jingfeng. Effectiveness of an Intelligent Voice Outbound Call System as an Adjunct to Usual Care for Health Management in Older Community-dwelling Patients with "Three Highs" Multimorbidity: a Randomized Controlled Trial [J]. Chinese General Practice, 2026, 29(31): 4635-4640. |
| [13] | SUN Xiuqin, FENG Zhenlong, WEI Lanxuan, ZENG Yuxin, LIU Jinbo, MA Lin, AN Zhantian, WANG Hongyu. Analysis of the Current Status of Metabolic Syndrome among Middle-aged and Elderly People in Shijingshan District, Beijing, and Its Behavioral and Lifestyle Influencing Factors [J]. Chinese General Practice, 2026, 29(30): 4424-4430. |
| [14] | LI Xiling, ZHANG Fan, YANG Xinyue, YANG Heng. Application of Exercise Snacks in Chronic Disease Management: a Scoping Review [J]. Chinese General Practice, 2026, 29(30): 4472-4479. |
| [15] | GUO Zhihong, CHEN Yingying, LIU Dewu. Efficacy and Safety of Antibiotic Bone Cement Combined with Vacuum Sealing Drainage for Diabetic Foot: a Meta-analysis [J]. Chinese General Practice, 2026, 29(30): 4503-4512. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||